DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20192910

Current clinical trends in the management of gram positive infections in Indian critical care settings: a survey

Ritika Rampal, Jaishid Ahdal, Kriti Kaushik, Rishi Jain

Abstract


Background: In India, gram-positive infections (GPIs) particularly, methicillin-resistant Staphylococcus aureus (MRSA) prevalence is reported to increase exponentially. The overall mortality rate among patients with multi drug resistant GPIs in ICU setting are as high as 16%, despite the availability of various therapeutic options. Aim of the study is to determine the burden of GPIs in critical care settings and to understand the practising behaviour among the specialists in the management of MRSA infections.

Methods: The survey was conducted among 264 critical care specialists who attended the Annual National Conference of Indian Society of Critical Medicine held in February 2019 at Mumbai. The delegates were administered a validated 10 question survey.

Results: In the survey, 72% of the respondents agreed to the rising prevalence of MRSA and associated increased mortality rate of >16%. Empirical gram positive cover is being given to 30-40% of ICU patients, with ABSSSI being listed as a major indication followed by CAP, VAP, CLABSI and DFI. 46% of the doctors listed vancomycin as their preferred anti-MRSA agents followed by teicolplanin and linezolid. However, more than 80% of the doctors feel that nephrotoxicity in vancomycin, thrombocytopenia in linezolid and poor biofilm penetration are major limitations of these anti-MRSA agents.

Conclusions: The survey highlighted the increasing trend in the prevalence and associated mortality in GPIs in critical care settings in India. Further, the limitations of existing anti-MRSA agents have invoked the need for a newer agent with a broad spectrum anti-bacterial activity along with improved safety profile and effective biofilm penetration, which can be used as a suitable alternative empiric therapy to manage GPIs.


Keywords


Biofilm, Gram positive infections, ICU infections, Linezolid, MRSA prevalence, Mortality, Vancomycin

Full Text:

PDF

References


John TJ, Dandona L, Sharma VP, Kakkar M. Continuing challenge of infectious diseases in India. Lancet. 2011;377:252‑69.

Laxminarayan R, Chaudhury RR. Antibiotic resistance in India: drivers and opportunities for action. PLoS Med. 2016;13(3):e1001974.

Divatia JV, Amin PR, Ramakrishnan N, Kapadia FN, Todi S, Sahu S, et al. Intensive care in India: The Indian intensive care case mix and practice patterns study. Indian J Crit Care Med. 2016;20(4):216.

Chatterjee S, Bhattacharya M, Todi SK. Epidemiology of adult-population sepsis in India: a single center 5 year experience. Indian J Crit Care Med. 2017;21(9):573-77.

Melzer M, Eykyn SJ, Gransden WR, Chinn S. Is methicillin-resistant Staphylococcus aureus more virulent than methicillin-susceptible S. aureus? A comparative cohort study of British patients with nosocomial infection and bacteremia. Clin Infect Dis. 2003;37(11):1453-60.

Center for Disease Dynamics, Economics & Policy. 2015. State of the World’s Antibiotics, 2015. CDDEP: Washington, D.C. Available at https://www.cddep.org/wp-content/uploads/2017/06/swa_executive_summary_edits_2016.pdf. Accessed 3rd May 2019.

National Treatment Guidelines for Antimicrobial Use in Infectious Diseases. 2016 - India. (2016; 64 pages). Available at http://pbhealth.gov.in/AMR_guideline7001495889.pdf. Accessed 3rd May 2019

Rajkumar S, Sistla S, Manoharan M, Sugumar M, Nagasundaram N, Parija SC, et al. Prevalence and genetic mechanisms of antimicrobial resistance in Staphylococcus species: a multicentre report of the indian council of medical research antimicrobial resistance surveillance network. Ind J Med Microbiol. 2017;35(1):53.

Haddadin AS, Fappiano SA, Lipsett PA. Methicillin resistant Staphylococcus aureus (MRSA) in the intensive care unit. Postgrad Med J. 2002;78(921):385-92.

Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK. Infectious Diseases Society of America. Clinical practice guidelines by the infectious disease’s society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18-55.

Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;14(1):73-156.

Appelbaum PC. The emergence of vancomycin‐intermediate and vancomycin‐resistant Staphylococcus aureus. Clin Microbiol Infect. 2006;12:16-23.

Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004;42(6):2398-402.

Burgess LD, Drew RH. Comparison of the incidence of vancomycin‐induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin‐tazobactam. Pharmacotherapy. J Human Pharmacol Drug Thera. 2014;34(7):670-6.

Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005;49(6):2260-6.

Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012;54(5):621-9.

Narita M, Tsuji BT, Yu VL. Linezolid‐associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy. J Human Pharmacol Drug Ther. 2007;27(8):1189-97.

Hanrahan TP, Kotapati C, Roberts MJ, Rowland J, Lipman J, Roberts JA, et al. Factors associated with vancomycin nephrotoxicity in the critically ill. Anaesth Intens Care. 2015;43(5):594-9.

Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA. 2009;302(21):2323-9.

Nazneen S, Mukta K, Santosh C, Borde A. Bacteriological trends and antibiotic susceptibility patterns of clinical isolates at Government Cancer Hospital, Marathwada. Ind J Cancer. 2016;53(4):583.

Sarvepalli AK, Dharana PK. Clinical profile, bacterial profile and outcomes of acute bacterial meningitis in a tertiary care hospital-one year study. Int J Adv Med. 2017;4:502.

Jindal N, Malhotra R, Grover P, Singh S, Bansal R, Kaur S. Methicillin resistant Staphylococcus aureus (MRSA) in Malwa region of Punjab (North-West India). Ind J Med Res. 2016;143(3):371-2.

Ray P, Manchanda V, Bajaj J, Chitnis DS, Gautam V, Goswami P, et al. Methicillin resistant Staphylococcus aureus (MRSA) in India: prevalence & susceptibility pattern. Ind J Med Res. 2013;137(2):363.

Neetu TJ, Murugan S. Genotyping of methicillin resistant Staphylococcus aureus from tertiary care hospitals in Coimbatore, South India. J Global Infect Dis. 2016;8:68-74.

National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32(8):470-85.

Gandra S, Tseng KK, Arora A, Bhowmik B, Robinson ML, Panigrahi B, et al. The mortality burden of multidrug-resistant pathogens in India: a retrospective observational study. Clin Infect Dis. 2018.

Siddiqui AH, Koirala J. Methicillin Resistant Staphylococcus Aureus (MRSA) [Updated 2018 Oct 27]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2019.

Chaudhry D, Prajapat B. Intensive care unit bugs in India: how do they differ from the Western world?. J Assoc Chest Physicians. 2017;5(1):10.

Sakoulas G, Moellering RC. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis. 2008;46(5):S360-7.

Dhand A, Sakoulas G. Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates (‘the MIC Creep’): implications for therapy. F1000 Med Rep. 2012;4:4.

Nguyen HM, Graber CJ. Limitations of antibiotic options for invasive infections caused by methicillin-resistant Staphylococcus aureus: is combination therapy the answer?. J Antimicrob Chemother. 2009;65(1):24-36.